

Carmine De Angelis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7735481/publications.pdf>

Version: 2024-02-01

88
papers

3,300
citations

159358

30
h-index

161609

54
g-index

92
all docs

92
docs citations

92
times ranked

5143
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
2	Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic. <i>Endocrinology</i> , 2022, 163, .	1.4	16
3	NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. <i>Scientific Reports</i> , 2022, 12, 1972.	1.6	7
4	Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, PD1-05-PD1-05.	0.4	0
5	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
6	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 813462.	1.3	2
7	Definition of High-Risk Early Hormone-Positive HER2–Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
8	Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment. <i>Genes</i> , 2022, 13, 682.	1.0	1
9	Prevalence of Sarcopenia in Women with Breast Cancer. <i>Nutrients</i> , 2022, 14, 1839.	1.7	9
10	Impaired seroconversion after SARS-COV-2 mRNA vaccine in patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8588-8588.	0.8	0
11	Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTO trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 522-522.	0.8	0
12	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	2.0	9
13	Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC). , 2021, , .		0
14	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	3.2	49
15	Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer. , 2021, , .		1
16	Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021, 11, 602523.	1.3	4
17	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. <i>Npj Breast Cancer</i> , 2021, 7, 63.	2.3	4
18	A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2–positive breast cancer. <i>FASEB Journal</i> , 2021, 35, e21719.	0.2	13

#	ARTICLE	IF	CITATIONS
19	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917.	1.0	2
20	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
21	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	3.2	31
22	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. <i>Translational Oncology</i> , 2020, 13, 262-274.	1.7	49
23	Towards personalized treatment for early stage HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 233-250.	12.5	166
24	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 821-827.	3.2	40
25	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885.	2.0	9
26	Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. <i>Nature Cell Biology</i> , 2020, 22, 701-715.	4.6	84
27	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409.	1.1	27
28	Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. <i>Nucleic Acids Research</i> , 2020, 48, 1800-1810.	6.5	15
29	Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		2
30	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1011-1011.	0.8	4
31	Palbociclib added to ongoing endocrine therapy for hormone receptor- positive HER2- negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460.	0.4	1
32	Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer. , 2020, , .		0
33	Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		0
34	Abstract P3-06-07: ADGRF1 overexpression inhibits tumor growth in vivo by inducing cell cycle arrest in HER2+ breast cancer. , 2020, , .		0
35	Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer. , 2020, , .		0
36	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1772.	1.0	36

#	ARTICLE	IF	CITATIONS
37	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	1.5	41
38	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 927-933.	0.6	37
39	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. <i>BMC Cancer</i> , 2019, 19, 220.	1.1	19
40	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	3.3	103
41	Ribociclib in HR+/HER2~ Advanced or Metastatic Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2019, 53, 501-509.	0.9	15
42	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. <i>British Journal of Cancer</i> , 2019, 120, 331-339.	2.9	48
43	Neratinib in HER2-Positive Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2019, 53, 612-620.	0.9	22
44	Molecular Mechanisms of Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 265-307.	0.2	5
45	Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , .		0
46	Abstract 3044: The role of GPR110 in tumorigenicity, tumor cell dissemination, and cell cycle regulation in HER2+ breast cancer. , 2019, , .		0
47	Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive<i>in vivo</i> breast cancer models. , 2019, , .		0
48	Abstract 2783: <i>OMICS</i> analysis of breast cancer PDX tumors to determine CTC-cluster-specific signature in predicting breast cancer metastasis. , 2019, , .		0
49	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
50	GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 279-292.	1.1	22
51	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2~ER~GREB1 Transcriptional Axis. <i>Cancer Research</i> , 2018, 78, 671-684.	0.4	80
52	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
53	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 38.	2.3	78
54	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	0.8	10

#	ARTICLE	IF	CITATIONS
55	Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications. <i>British Journal of Cancer</i> , 2017, 116, 821-827.	2.9	14
56	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4482-E4491.	3.3	83
57	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	3.2	85
58	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017, 17, 559-563.	1.1	12
59	The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. <i>Current Oncology Reports</i> , 2017, 19, 35.	1.8	80
60	PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. <i>Npj Breast Cancer</i> , 2017, 3, 45.	2.3	21
61	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46
62	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017, 31, 114-120.	0.9	49
63	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017, 8, 115709-115717.	0.8	18
64	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017, 8, 112816-112824.	0.8	3
65	Tumor characteristics and prognosis in familial breast cancer. <i>BMC Cancer</i> , 2016, 16, 924.	1.1	24
66	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6600-E6609.	3.3	119
67	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016, 14, 470-481.	1.5	39
68	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 608-608.	0.8	1
69	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016, 11, e0159146.	1.1	3
70	Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 127-132.	1.1	33
71	Resistance to Anti-HER2 Therapies in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e157-e164.	1.8	24
72	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	3.2	82

#	ARTICLE	IF	CITATIONS
73	ESR1 mutationsâ€”a mechanism for acquired endocrine resistance in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 573-583.	12.5	458
74	Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122.	0.7	8
75	The changing role of ER in endocrine resistance. <i>Breast</i> , 2015, 24, S60-S66.	0.9	97
76	Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib. , 2015, , .		0
77	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11573-e11573.	0.8	0
78	Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance. , 2015, , .		0
79	Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models. , 2015, , .		0
80	Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-571.	0.8	5
81	PO70 CLINICAL BENEFIT OF FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER ACCORDING TO PRIOR THERAPY. <i>Breast</i> , 2013, 22, S44.	0.9	0
82	Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. <i>Combination Products in Therapy</i> , 2013, 3, 25-37.	1.1	1
83	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-e133.	0.6	2
84	Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to prior therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11528-e11528.	0.8	0
85	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 795-804.	1.1	175
86	Overcoming Treatment Resistance in HER2-Positive Breast Cancer. <i>Drugs</i> , 2012, 72, 1175-1193.	4.9	38
87	Breast cancer prognosis in <i>BRCA1/2Â </i>mutation carriers: A case control study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1554-1554.	0.8	0
88	Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. <i>Oncology</i> , 2009, 77, 23-37.	0.9	47